Cultivating Virtue to Advance Surgery · Upholding the Way in Clinical Excellence | Xuesong Li’s Team Completes the First Fully Intracorporeal Autologous Kidney Transplant Using a Domestic Surgical Robot

Cultivating Virtue to Advance Surgery · Upholding the Way in Clinical Excellence | Xuesong Li’s Team Completes the First Fully Intracorporeal Autologous Kidney Transplant Using a Domestic Surgical Robot

Recently, the upper urinary tract reconstruction team led by Xuesong Li, Director of the Department of Urology at Peking University First Hospital, successfully performed a domestic surgical robot–assisted laparoscopic fully intracorporeal autologous kidney transplantation for a patient with complex upper urinary tract obstruction.
Breast Cancer Chronicle · 2025 Professor Jin Yang: Breakthroughs from the ASCENT and TROPION Programs Signal the Dawn of Precision Therapy for Advanced Triple-Negative Breast Cancer

Breast Cancer Chronicle · 2025 Professor Jin Yang: Breakthroughs from the ASCENT and TROPION Programs Signal the Dawn of Precision Therapy for Advanced Triple-Negative Breast Cancer

The evolution of breast cancer diagnosis and treatment is an epic journey spanning past and present, marked by transformative breakthroughs that have profoundly reshaped patient outcomes. From January 9 to 11, 2026, the Northern China Breast Cancer Salon · Annual Progress Review was held in Beijing. One of the most highly anticipated sessions was the Annual Review of Advances in Breast Cancer Therapy, which brought together leading experts to examine and synthesize the most significant international and domestic developments of 2025. Topics ranged from surgery, pathology, and radiotherapy to molecular classification and precision treatment, highlighting studies that have reshaped clinical practice.
Professor Honghu Zhu: Advances, Evolution, and Future Directions of Hematopoietic Stem Cell Transplantation in Acute Leukemia丨2026 CSCO Academic Conference on Hematologic Malignancies

Professor Honghu Zhu: Advances, Evolution, and Future Directions of Hematopoietic Stem Cell Transplantation in Acute Leukemia丨2026 CSCO Academic Conference on Hematologic Malignancies

From January 16 to 18, 2026, the Working Meeting of the Chinese Society of Clinical Oncology (CSCO) Leukemia, Lymphoma, and Myeloma Expert Committee and the 2026 CSCO Academic Conference on Hematologic Malignancies were held in Haikou, China. During the meeting, Professor Honghu Zhu of Beijing Chaoyang Hospital, Capital Medical University, provided a comprehensive overview of the current challenges of hematopoietic stem cell transplantation (HSCT) in acute leukemia, the evolution of transplant indications in the era of novel agents, and future optimization strategies. His insights offered important guidance for clinicians seeking to refine treatment approaches.
CASH 2026 Professor Wenbin Qian: Advancing Fourth-Generation CAR-T Therapy—Decoding Long-Term Efficacy, Resistance Mechanisms, and Future Directions

CASH 2026 Professor Wenbin Qian: Advancing Fourth-Generation CAR-T Therapy—Decoding Long-Term Efficacy, Resistance Mechanisms, and Future Directions

With continuous technological iteration in CAR-T cell therapy, fourth-generation CAR-T is increasingly demonstrating substantial clinical potential. From January 9 to 11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was grandly held in Tianjin. The meeting brought together leading hematology experts from China and abroad, focusing on cutting-edge advances and national health strategy priorities, fostering in-depth academic exchange and exploration of new directions in the field.
CASH 2026 Professor Jun Shi: New Insights into the Immune Mechanisms of Aplastic Anemia — Targeting CD38 and the JAK Pathway Shows Promising Therapeutic Potential

CASH 2026 Professor Jun Shi: New Insights into the Immune Mechanisms of Aplastic Anemia — Targeting CD38 and the JAK Pathway Shows Promising Therapeutic Potential

Aplastic anemia (AA) is an immune-mediated bone marrow failure syndrome that poses significant clinical challenges due to marked patient heterogeneity, a high proportion of relapsed or refractory cases, and limited options for precision-based interventions. From January 9 to 11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was grandly held in Tianjin. The conference brought together leading hematology experts from China and abroad, focusing on cutting-edge scientific advances and national health strategy priorities, fostering in-depth academic exchange and exploration of future directions in the field.
Lymphoma Roundtable · ASH Special Professor Qingqing Cai: New Advances in Bispecific Antibody Therapy for Relapsed/Refractory Lymphoma

Lymphoma Roundtable · ASH Special Professor Qingqing Cai: New Advances in Bispecific Antibody Therapy for Relapsed/Refractory Lymphoma

The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) was recently successfully held in Orlando, United States. As the year’s flagship event in hematology, the meeting presented a concentrated series of groundbreaking advances in lymphoma research, offering new directions for the optimization of clinical practice.
Professor Hailiang Zhang Provides an In-Depth Interpretation of the 2026 NCCN Kidney Cancer Guideline Updates: What New Clinical Insights Arise from the Elevated Role of Radiotherapy and Optimized Immunotherapy Stratification?

Professor Hailiang Zhang Provides an In-Depth Interpretation of the 2026 NCCN Kidney Cancer Guideline Updates: What New Clinical Insights Arise from the Elevated Role of Radiotherapy and Optimized Immunotherapy Stratification?

Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The meeting focused on cutting-edge topics in the diagnosis and treatment of urologic malignancies, aiming to establish a high-level academic exchange platform and to promote innovation in clinical thinking and standardized practice among young physicians.
Professor Yige Bao: From “New Leaves Spur the Old” to “One Mountain Opens, Another Blocks the Way” —Reflections and Challenges in Post-Neoadjuvant Management of MIBC

Professor Yige Bao: From “New Leaves Spur the Old” to “One Mountain Opens, Another Blocks the Way” —Reflections and Challenges in Post-Neoadjuvant Management of MIBC

Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The meeting focused on the latest frontiers in urologic oncology and brought together many leading mid-career and young experts from across China, aiming to elevate clinical practice through intellectual exchange.
ESMO Hot Topic Focus | Professor Richard S. Finn: Immunotherapy-Based Combinations Turn “Stone into Gold” — The TALENTOP Study Reshapes the Treatment Landscape of Advanced HCC

ESMO Hot Topic Focus | Professor Richard S. Finn: Immunotherapy-Based Combinations Turn “Stone into Gold” — The TALENTOP Study Reshapes the Treatment Landscape of Advanced HCC

In the global field of hepatocellular carcinoma (HCC) treatment, the synergistic use of targeted therapy and immunotherapy has led to breakthrough progress, significantly prolonging survival for patients with advanced disease and bringing renewed hope to countless individuals. Yet medical progress never stands still. How to further transcend existing treatment paradigms and unlock deeper survival benefits remains a persistent goal for clinicians worldwide.